ROSEVILLE, Minn., Oct. 17, 2016 /PRNewswire/ -- Rebiotix Inc., a clinical-stage biotechnology company focused on
The late-breaking oral presentation, "RBX2660, a microbiota-based drug for the prevention of recurrent Clostridium difficile infection, is safe and effective: results from a randomised, double-blinded, placebo-controlled trial," (Abstract #LB08) will be presented by Robert Orenstein, D.O., an Associate Professor of Medicine and the Chair of the Division of Infectious Diseases at Mayo Clinic in Arizona, and study investigator on Monday, October 17, 2016, at 3:45-3:57 pm CET.
Additionally, data from the PUNCH™ CD2 clinical trial will be the subject of three poster presentations at American College of Gastroenterology (ACG) 2016 to be held October 14-19, 2016 in Las Vegas, Nevada:
Lee Jones, co-founder, president and CEO, commented, "We are excited for the opportunity to have data from our Phase 2b clinical trial of RBX2660 presented at UEG Week 2016 and ACG 2016, two of the preeminent gastroenterology conferences in the world. Based on the results of the PUNCH™ CD2 study, our plan is to advance the clinical development of RBX2660 into a Phase 3 trial in recurrent C.diff. with the ultimate goal of bringing to market a drug product that addresses this critically important and potentially life-threatening disease."
About Rebiotix Inc.Rebiotix Inc. is a clinical-stage biotechnology company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix is the most clinically advanced microbiome company in the industry, with its Phase 3-ready drug candidate, RBX2660, having successfully completed a Phase 2b randomized, double-blind, placebo-controlled trial as a possible prevention of recurrent Clostridium difficile (C.diff.) infection after a standard of care course of antibiotics (PUNCH™ CD2). RBX2660 has been granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential to treat recurrent C.diff. infection. Rebiotix's development pipeline includes multiple formulations targeting several disease indications and is built around its pioneering Microbiota Restoration Therapy (MRT) platform. MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad spectrum of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
Rebiotix Media Contact: Amy Wheeler Tiberend Strategic Advisors 646-362-5750 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-from-rebiotixs-phase-2b-trial-of-lead-microbiota-based-drug-candidate-rbx2660-to-be-featured-in-late-breaking-oral-presentation-at-ueg-week-2016-300345771.html
SOURCE Rebiotix Inc.
Subscribe to our Free Newsletters!
Proper understanding of waste collection, segregation and management is required to reduce the ...
Leukoplakia refers to a painless, raised white patch in the mouth that does not go away on rubbing, ...
Health insurance has emerged one of the fastest growing segments in the non-life insurance industry ...View All